May 27, 2020
ESSA Pharma to Present at Jefferies Virtual Healthcare Conference
Apr 08, 2020
Trovagene to Present at the 19th Annual Needham Healthcare Conference
Mar 31, 2020
ESSA Pharma Submits IND for EPI-7386 for Prostate Cancer and Provides Business Update
Feb 27, 2020
ESSA Pharma Inc. Reports Results of Annual General and Special Meeting of Shareholders
Feb 11, 2020
Phosplatin Therapeutics Presents Positive Data from Two Phase I Studies in Metastatic Castrate-Resistant Prostate Cancer Patients at the 2020 Genitourinary Cancers Symposium
Oct 18, 2019
ESSA Announces Changes to its Board of Directors
Oct 03, 2019
Janssen Announces U.S. FDA Breakthrough Therapy Designation Granted for Niraparib for the Treatment of Metastatic Castration-Resistant Prostate Cancer
Sep 19, 2019
ESSA to Present at Ladenburg Thalmann Healthcare Conference
Sep 05, 2019
ESSA Pharma to Present at H.C. Wainwright 21st Annual Global Investment Conference
Aug 15, 2019
Trovagene to Present New Data from Onvansertib Phase 2 Study in Metastatic Castration-Resistant Prostate Cancer at Asia-Pacific Prostate Cancer Conference
Jun 26, 2019
ESSA Provides an Update to the Acquisition of Realm Therapeutics
Jun 21, 2019
ESSA Pharma to Hold Annual Shareholders' Meeting and Announces Three Realm-Nominated Directors
May 10, 2019
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Second Quarter Ended March 31, 2019
Apr 17, 2019
ESSA Pharma Announces Abstract Presentation at the 2019 American Urological Association Annual Meeting
Mar 21, 2019
Epic Sciences to Present New Data at AACR 2019 Demonstrating Expansion of Functional Cell Profiling Technology into New Indications including Breast, Lung and Prostate Cancer
Feb 14, 2019
Janssen Announces Preliminary Results from Phase 2 GALAHAD Study in Adults with Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Pathway Defects (DRD)
Feb 11, 2019
ESSA Pharma Announces Two Abstracts Selected to be Presented at the 2019 Genitourinary Cancers Symposium
Jun 27, 2018
Kangpu Biopharmaceuticals Launched Phase I Study of Novel Cancer Therapy Candidate KPG-121 in Patients with Metastatic Castration-Resistant Prostate Cancer in Collaboration with Accelovance, Inc.